This study tests an experimental drug called NS-050/NCNP-03 in 20 boys aged 4 to 16 with Duchenne muscular dystrophy (DMD), a genetic condition that causes progressive muscle weakness. The drug aims to help muscles produce a needed protein by skipping a faulty section of the gene…
Phase: PHASE1, PHASE2 • Sponsor: NS Pharma, Inc. • Aim: Disease control
Last updated May 15, 2026 11:53 UTC